Cadila Healthcare rose 3.67% to Rs 1,235.70 at 12:50 IST on BSE after the company said Zydus Cadila has received the final approval from the US drug regulator to sell anti-viral drug in multiple strengths in the US market.
The company made the announcement during trading hours today, 20 August 2014.
Meanwhile, the BSE Sensex was down 75.72 points, or 0.29%, to 26,344.95.
On BSE, so far 12,000 shares were traded in the counter, compared with an average volume of 17,261 shares in the past one quarter.
The stock hit a high of Rs 1,239 and a low of Rs 1,190 so far during the day. The stock hit a 52-week high of Rs 1,239 on 20 August 2014. The stock hit a 52-week low of Rs 631 on 20 August 2013.
The stock had outperformed the market over the past one month till 19 August 2014, rising 10.88% compared with 3.04% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 32.59% as against Sensex's 8.45% rise.
More From This Section
The large-cap company has an equity capital of Rs 102.37 crore. Face value per share is Rs 5.
Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Acyclovir tablets in the strengths of 400 milligram (mg) and 800 mg. The drug falls under the anti-viral segment.
The estimated sales in 2014 for Acyclovir tablets is $55.80 million, as per 1MS.
The group now has 95 approvals and has so far filed 249 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in fiscal year ended March 2004, the company said in a statement.
On a consolidated basis, Cadila Healthcare's net profit rose 23.1% to Rs 240.21 crore on 24.9% increase in total income to Rs 2060.53 crore in Q1 June 2014 over Q1 June 2013.
Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Powered by Capital Market - Live News